FDA inspection and enforcement activity is moving faster, becoming more data-informed, and placing greater pressure on companies to prove control before, during, and after inspection.
That matters for every biologics, cell and gene therapy, and CDMO-dependent company moving toward BLA, prelicense, or preapproval inspection.
FDA does not evaluate the submission in isolation. The agency sends investigators to verify that the manufacturing operation, quality system, validation decisions, records, investigations, CAPAs, and CDMO oversight can actually support what was submitted. The CMC narrative and the site reality have to match, and they have to hold up under direct questioning.
Here is what many teams underestimate until it is too late.
Companies that get into trouble at this stage are rarely underprepared scientifically. They are underprepared operationally. Records are difficult to retrieve. Deviation investigations are thin. CAPAs were closed but not proven effective. CDMO oversight documentation does not demonstrate real control. Validation decisions are not well defended.
Those gaps may not be obvious in the submission. All of them become visible during inspection.
Strong companies pressure test this before FDA does. They work through the operation systematically, identify where the gaps are between what was submitted and what can be defended, and build the structure needed to close them before the investigator arrives.
That is exactly the work MEDVACON does with biologics and advanced therapy companies approaching BLA, prelicense, and preapproval pressure: bringing structure, ownership, and execution discipline across quality systems, validation, remediation, CDMO oversight, and inspection readiness.
Built to hold up, not just to look complete.
Because approval readiness is not just about submitting the story. It is about proving the system behind the story can stand up.